| Literature DB >> 34097506 |
Irina N Baranova1, Alexander V Bocharov1, Tatyana G Vishnyakova1, Zhigang Chen1, Anna A Birukova2, Yunbo Ke3, Xuzhen Hu4, Peter S T Yuen4, Robert A Star4, Konstantin G Birukov3, Amy P Patterson1,5, Thomas L Eggerman1,6.
Abstract
Recent studies suggest an anti-inflammatory protective role for class B scavenger receptor BI (SR-BI) in endotoxin-induced inflammation and sepsis. Other data, including ours, provide evidence for an alternative role of SR-BI, facilitating bacterial and endotoxin uptake and contributing to inflammation and bacterial infection. Enhanced endotoxin susceptibility of SR-BI-deficient mice due to their anti-inflammatory glucocorticoid deficiency complicates the understanding of SR-BI's role in endotoxemia/sepsis, calling for the use of alternative models. In this study, using human SR-BI (hSR-BI) and hSR-BII transgenic mice, we found that SR-BI and, to a lesser extent, its splicing variant SR-BII protect against LPS-induced lung damage. At 20 h after intratracheal LPS instillation, the extent of pulmonary inflammation and vascular leakage was significantly lower in hSR-BI and hSR-BII transgenic mice than in wild-type mice. Higher bronchoalveolar lavage fluid (BALF) inflammatory cell count and protein content and lung tissue neutrophil infiltration found in wild-type mice were associated with markedly (2 to 3 times) increased proinflammatory cytokine production compared to these parameters in transgenic mice following LPS administration. The markedly lower endotoxin levels detected in BALF of transgenic versus wild-type mice and the significantly increased BODIPY-LPS uptake observed in lungs of hSR-BI and hSR-BII mice 20 h after the i.t. LPS injection suggest that hSR-BI- and hSR-BII-mediated enhanced LPS clearance in the airways could represent the mechanism of their protective role against LPS-induced acute lung injury.Entities:
Keywords: LPS; SR-BI; SR-BII; acute lung injury; class B scavenger receptors; inflammation; lipopolysaccharide; proinflammatory cytokines
Mesh:
Substances:
Year: 2021 PMID: 34097506 PMCID: PMC8445172 DOI: 10.1128/IAI.00301-21
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.609